Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Biogen Cuts Alzheimer’s Drug Price 50% Months After Approval (2)

Dec. 20, 2021, 3:03 PM

Biogen Inc. said it would cut the wholesale price of its Alzheimer’s disease drug Aduhelm in half in the U.S., a move that comes after the treatment’s high cost spurred concerns that it could strain Medicare and insurers.

The company said in a statement on Monday that it would reduce the annual list price of the treatment to $28,200 to lower out-of-pocket costs for patients and reduce “the potential financial implications for the U.S. health-care system.”

It is unusual for pharmaceutical companies to drastically reduce the cost of a medication soon after it is approved. Aduhelm won backing from the ...